Participated · Seed · Jul 2026

EELI Technology develops modular, field-deployable electrochemical systems designed to recover lithium and other critical minerals from low-grade or chemically complex sources. The team, led by founder Mert Akin, Ph.D., has its technology roots in programs such as Activate and Cyclotron Road at Berkeley Lab. EELI recently closed an oversubscribed $2 million pre-seed round to accelerate commercialization and expand operations. Over the next 18 months the company plans to build commercial-scale pilot systems, expand its Hayward, California technology development and manufacturing facility, and prepare for initial U.S. customer-site deployments. EELI has also received support from the California Energy Commission and the U.S. Department of Energy as it moves from research to commercial pilots.

Participated · Series B · Jul 2026

Quaise Energy develops superhot geothermal power systems and the millimeter wave drilling technology to access deep, high-temperature rock. Its drilling approach, developed after research at MIT, ablates rock and aims to reach temperatures of roughly 300–500°C at depths beyond what conventional drilling can economically access. The company has demonstrated field progress, drilling more than 100 meters through granite in 2025 and is approaching one kilometer of depth at its Central Texas site. Quaise is both a technology innovator and project developer and is constructing Project Obsidian on federal geothermal leases in Oregon with construction underway. The company says Project Obsidian has gigawatt-scale potential and plans to deliver first electrons to the grid by 2030. Quaise has raised $230 million to date, with the recent $134 million Series B serving as the initial equity component of a broader capital program that includes project-level equity and debt.

Participated · Seed · Apr 2026

CavilinQ is developing cavity-enhanced photonic links that aim to connect individual quantum processors into unified, modular clusters to enable larger-scale quantum computing. The platform is described as hardware-agnostic, with initial demonstrations planned for integration with neutral atom quantum processors. Its technology builds on high-fidelity light-matter interfaces advanced by scientific co-founders Mikhail Lukin and Hannes Bernien. The company plans to establish a specialized laboratory in Cambridge, Massachusetts, expand its team, and reach key technical milestones. CavilinQ announced a completed $8.8 million seed round to fund these efforts. The company positions its interconnects as enabling distributed quantum architectures that could scale performance and reliability beyond isolated processors.

Participated · Equity · Apr 2026

Via Separations develops modular filtration process solutions that electrify chemical separations, claiming reductions in energy needed for separations by up to 90 percent. Its technology has proven commercial performance in the pulp and paper sector, and the company plans to accelerate deployment into the refining and chemical industries. Via’s solutions aim to lower energy use, improve uptime and strengthen operational resilience while reducing emissions. The company is led by CEO Shreya Dave and recently raised $36M in new funding from a group including Climate Investment, Aramco Ventures and Marathon Petroleum Corporation, alongside existing investors.

Led · Seed · Feb 2026

GelMEDIX is building regenerative ophthalmic therapies around a proprietary injectable hydrogel scaffold that is delivered as a liquid and light-activated in situ to form a biocompatible, biodegradable matrix. The platform is engineered to protect transplanted cells during injection, localize them at the target site, and promote integration and tissue regeneration, thereby improving the safety and efficacy of cell and gene therapies. Its lead candidate, GMX-101, combines the scaffold with iPSC-derived retinal pigment epithelial cells to replace damaged tissue and halt disease progression in late-stage Geographic Atrophy; preclinical studies have shown improved cell survival, engraftment, and vision preservation. Beyond internal programs, GelMEDIX has signed its first strategic collaboration with a global pharmaceutical company that will pair the scaffold with multiple stem cell lines to create new cell therapies. Proceeds from the recent $13 million seed round will fund advancement of GMX-101 toward the clinic and further validation of the hydrogel platform. The company also added MIT Professor Michael J. Cima and Safar Partners’ Parinaz Motamedy to its board, reinforcing technical and investor support.